251 related articles for article (PubMed ID: 28148938)
21. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
22. Investigational drug access taken to task in lawsuit against FDA.
Randal J
J Natl Cancer Inst; 2003 Dec; 95(24):1818-20. PubMed ID: 14679146
[No Abstract] [Full Text] [Related]
23. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
Goozner M
J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
[No Abstract] [Full Text] [Related]
24. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
Finkelstein PE
AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
[No Abstract] [Full Text] [Related]
25. Patient group seeks overhaul of FDA clinical trial system in court.
Hede K
J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
[No Abstract] [Full Text] [Related]
26. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
Khozin S; Liu K; Jarow JP; Pazdur R
Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
[No Abstract] [Full Text] [Related]
27. Market watch: Upcoming market catalysts in Q1 2014.
Stopke E
Nat Rev Drug Discov; 2014 Jan; 13(1):11. PubMed ID: 24378790
[No Abstract] [Full Text] [Related]
28. Drug development process for a product with a primary pediatric indication.
Allen AJ; Michelson D
J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
[TBL] [Abstract][Full Text] [Related]
29. Accelerated approval regulations may need overhaul, panel suggests.
Finkelstein JB
J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
[No Abstract] [Full Text] [Related]
30. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.
Bateman-House A; Robertson CT
JAMA Intern Med; 2018 Mar; 178(3):321-322. PubMed ID: 29356821
[No Abstract] [Full Text] [Related]
31. The FDA just says yes.
MacPherson P
Hosp Health Netw; 1996 May; 70(10):34-6, 38. PubMed ID: 8620201
[TBL] [Abstract][Full Text] [Related]
32. Practical, legal, and ethical issues in expanded access to investigational drugs.
Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952
[No Abstract] [Full Text] [Related]
33. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
34. Market watch: Upcoming market catalysts in Q1 2017.
Fulton Z
Nat Rev Drug Discov; 2016 Dec; 16(1):11. PubMed ID: 28031567
[No Abstract] [Full Text] [Related]
35. Individual patient treatment use of unapproved drugs: a new option for the seriously ill.
Simon LS; Green A
J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):19-22. PubMed ID: 20345195
[TBL] [Abstract][Full Text] [Related]
36. Clinical development success rates for investigational drugs.
Hay M; Thomas DW; Craighead JL; Economides C; Rosenthal J
Nat Biotechnol; 2014 Jan; 32(1):40-51. PubMed ID: 24406927
[No Abstract] [Full Text] [Related]
37. White House announces cancer-drug initiatives.
Am J Health Syst Pharm; 1996 May; 53(10):1110. PubMed ID: 8734669
[No Abstract] [Full Text] [Related]
38. Market watch: Upcoming market catalysts in Q3 2015.
Tan C
Nat Rev Drug Discov; 2015 Jul; 14(7):451. PubMed ID: 26092947
[No Abstract] [Full Text] [Related]
39. The terminally ill, access to investigational drugs, and FDA rules.
Blake V
Virtual Mentor; 2013 Aug; 15(8):687-91. PubMed ID: 23937785
[No Abstract] [Full Text] [Related]
40. Drug approval and AIDS: benefits for the elderly.
Rothman DJ; Edgar H
Health Aff (Millwood); 1990; 9(3):123-30. PubMed ID: 2227773
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
